In renal transplantation, monitoring the risk of subclinical rejection and graft failure remains challenging. Economic efficiency will be evaluated during the trial. We will integrate users’ perspectives by performing sociological interviews to promote the involvement of patients in their clinical care and to help clinicians in decision‐making. Ancillary functional studies will reinforce AGORA to assess immunological events following immunosuppression minimization. AGORA could impact health care pathway for kidney transplant recipients by incorporating a medical decision tool for personalising immunosuppressive therapy.